SIRION Biotech

An alliance has been formed between SIRION Biotech and Heidelberg University Hospital for the development of novel AAV capsids and technologies addressing shortcomings of clinical gene therapy trials. Read more


Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. Read more


German-based company, SIRION Biotech has signed a two-year development agreement with a clinical-stage ophthalmology company, Acucela, to establish optimised adeno associated virus (AAV) vectors for clinical applications in ocular gene therapy. Read more


A strategic partnership has been signed between SIRION Biotech and Vibalogics for the development of a new service offering that will allow the companies to cater for start-to-finish adeno-associated virus (AAV) service. Read more